风湿病患者急性COVID-19后DMARD中断、风湿病复发及COVID-19症状持续时间延长:一项前瞻性研究
该前瞻性研究调查了174例既往患有系统性自身免疫性风湿病(SARD)且确诊COVID-19的患者,发现51%的DMARD使用者报告用药方案中断,41%报告SARD复发,45%出现症状持续≥28天。COVID-19住院(OR 3.54,95%CI 1.27-9.87)和初始症状数量(每症状OR 1.38,95%CI 1.17-1.63)与症状持续时间延长相关。
要点
- 51%的DMARD使用者报告COVID-19后用药方案中断,41%报告SARD复发。
- 45%的患者COVID-19症状持续≥28天,中位缓解时间为25天(IQR 11,160)。
- COVID-19住院和初始症状数量与症状持续时间延长相关。
核心结论
- 在这项针对COVID-19幸存者的前瞻性研究中,DMARD中断、SARD复发和COVID-19症状持续时间延长较为常见,提示急性COVID-19后对SARD有实质性影响。
研究设计与样本
- 前瞻性研究,调查了174例既往患有SARD且确诊COVID-19的COVID-19幸存者,调查时间为2021年3月至2022年1月。
- 采用逻辑回归分析COVID-19症状持续时间延长(定义为持续≥28天)的基线预测因素。
主要发现
- 127名使用任何DMARD的受访者中,51%报告COVID-19发病后用药方案中断。
- 除羟氯喹(23%)和利妥昔单抗(46%)外,各DMARD有任一变化的比例为56-77%。
- 41%报告COVID-19后SARD复发。
- 调查时患者报告的总体疾病活动度较COVID-19前更差(均值6.6±2.9 vs 7.6±2.3,p<0.001)。
- COVID-19症状中位缓解时间为25天(IQR 11,160),45%出现症状持续≥28天。
关键数值与推荐
- COVID-19住院与症状持续时间延长相关(OR 3.54,95%CI 1.27-9.87)。
- 初始COVID-19症状数量与症状持续时间延长相关(每症状OR 1.38,95%CI 1.17-1.63)。
- 症状持续时间延长者较无延长者RAPID3评分更高(p=0.007)、疼痛更多(p<0.001)、疲劳更多(p=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 survivors with systemic autoimmune rheumatic diseases (SARDs). METHODS: We surveyed people with pre-existing SARDs who had confirmed COVID-19 at Mass General Brigham to investigate post-acute sequelae of COVID-19. We obtained data on demographics, clinical characteristics, COVID-19 symptoms/course, and patient-reported measures. We examined baseline predictors of prolonged COVID-19 symptom duration (defined as lasting ≥28 days) using logistic regression. RESULTS: We analyzed surveys from 174 COVID-19 survivors (mean age 52 years, 81% female, 80% White, 50% rheumatoid arthritis) between March 2021 and January 2022. Fifty-one percent of 127 respondents on any DMARD reported a disruption to their regimen after COVID-19 onset. For individual DMARDs, 56-77% had any change, except for hydroxychloroquine (23%) and rituximab (46%). SARD flare after COVID-19 was reported by 41%. Global patient-reported disease activity was worse at the time of survey than before COVID-19 (mean 6.6±2.9 vs. 7.6±2.3, p<0.001). Median time to COVID-19 symptom resolution was 25 days (IQR 11, 160). Prolonged symptom duration of ≥28 days occurred in 45%. Hospitalization for COVID-19 (OR 3.54, 95%CI 1.27-9.87) and initial COVID-19 symptom count (OR 1.38 per symptom, 95%CI 1.17-1.63) were associated with prolonged symptom duration. Respondents experiencing prolonged symptom duration had higher RAPID3 scores (p=0.007) and more pain (p<0.001) and fatigue (p=0.03) compared to those without prolonged symptoms. CONCLUSION: DMARD disruption, SARD flare, and prolonged COVID-19 symptom duration were common in this prospective study of COVID-19 survivors, suggesting substantial impact on SARDs after acute COVID-19.
引用
- Di Iorio M, Cook CE, Vanni KMM, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022. PMID: 35617780. doi:10.1016/j.semarthrit.2022.152025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。